著者

吉位 尚 濱本 嘉彦 村岡 重忠 糀谷 淳 古土井 春吾 麻柄 真也 大塚 芳基 中尾 薫 寺延 治 島田 桂吉 古森 孝英

出版者

特定非営利活動法人 日本口腔科学会

雑誌

日本口腔科学会雑誌 (ISSN:00290297)

巻号頁・発行日

vol.48, no.6, pp.479-488, 1999-11-10 (Released:2011-09-07)

参考文献数

47

被引用文献数

5

---

The clinical efficacy of long-term roxithromycin (RXM) treatment was examined objectively in 8 patients with chronic diffuse sclerosing mandibular osteomyelitis. RXM was administered orally at a dose of 300mg per day for 68 days to 66 months.As a result, the results of 7 out of 8 cases (87.5%) were assessed effective, and the symptoms had disappeared in 1 to 12 months. One case assessed poor had several operations and various kinds of antibiotic therapy for more than 11 years before this therapy. In 7 cases assessed effective, the improvement of osteolytic changes on X-ray was observed. However, most of the X-ray findings remained osteosclerosis or the osteosclerosis became more predominant, when this therapy was terminated. It was considered that X-ray findings would take a long time to be normalized. Therefore, the optimum duration of administration which is the time to terminate this therapy should be decided according to the improvement of symptoms along with the disappearance of osteolytic findings on X-ray. Diarrhea and stomach discomfort in 1 case, and liver dysfunction in 1 case were found, however, these side effects were slight.The mechanisms of RXM are unclear however, these results indicate that long-term RXM treatment has therapeutic possibilities for diffuse sclerosing mandibular osteomyelitis and should be used as the first choice followed by surgical treatment if necessary.